M
Michele Colledan
Researcher at University of Milan
Publications - 230
Citations - 5711
Michele Colledan is an academic researcher from University of Milan. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 35, co-authored 202 publications receiving 4515 citations. Previous affiliations of Michele Colledan include ISMETT & University of Rome Tor Vergata.
Papers
More filters
Journal ArticleDOI
Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study.
Pace participants,Riccardo A. Audisio,Daniel Pope,Hodigere S. J. Ramesh,R. Gennari,B.L. van Leeuwen,Christopher R. West,G. Corsini,Massimo Maffezzini,Harald J. Hoekstra,D. Mobarak,Federico Bozzetti,Michele Colledan,Hans Wildiers,A. Stotter,A Capewell,E Marshall +16 more
TL;DR: PACE represents a valuable tool in enhancing the decision process concerning the candidacy of elderly cancer patients for surgical intervention and can reduce inappropriate age-related inequity in access to surgical intervention.
Journal ArticleDOI
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Edward K. Geissler,Andreas A. Schnitzbauer,Andreas A. Schnitzbauer,Carl Zülke,P. Lamby,Andrea Proneth,Christophe Duvoux,Patrizia Burra,Karl-Walter Jauch,Markus Rentsch,Tom M. Ganten,Jan Schmidt,Utz Settmacher,Michael Heise,Michael Heise,Giorgio Rossi,Umberto Cillo,Norman M. Kneteman,René Adam,Bart van Hoek,Philippe Bachellier,Philippe Wolf,Lionel Rostaing,Wolf O. Bechstein,Magnus Rizell,James J. Powell,Ernest Hidalgo,J. Gugenheim,Heiner Wolters,Jens Brockmann,André Roy,Ingrid Mutzbauer,Angela Schlitt,Susanne Beckebaum,Christian Graeb,Silvio Nadalin,Umberto Valente,Victor Sanchez Turrion,Neville V. Jamieson,T. Scholz,Michele Colledan,Fred Fändrich,Thomas Becker,Gunnar Söderdahl,Olivier Chazouillères,Heikki Mäkisalo,Georges-Philippe Pageaux,Rudolf Steininger,Thomas Soliman,Koert P. de Jong,Jacques Pirenne,Raimund Margreiter,Johann Pratschke,Antonio Daniele Pinna,Johann Hauss,Stefan Schreiber,Simone I. Strasser,Jürgen Klempnauer,Roberto Troisi,Sherrie Bhoori,Jan Lerut,Itxarone Bilbao,Christian Klein,Alfred Königsrainer,Darius F. Mirza,Gerd Otto,Vincenzo Mazzaferro,Peter Neuhaus,Hans J. Schlitt +68 more
TL;DR: This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC and reveals that low-risk, rather than high- risk, patients benefited most from sirolimus; furthermore, younger recipients (age ⩽60) also benefited, as well siro Limus monotherapy patients.
Journal ArticleDOI
2018 annual report of the European Liver Transplant Registry (ELTR) – 50‐year evolution of liver transplantation
René Adam,Vincent Karam,Valérie Cailliez,John G. O Grady,Darius F. Mirza,Daniel Cherqui,Jürgen Klempnauer,Mauro Salizzoni,Johann Pratschke,Neville V. Jamieson,Ernest Hidalgo,Andreas Paul,Rafael López Andújar,Jan Lerut,Lutz Fisher,Karim Boudjema,Constantino Fondevila,Olivier Soubrane,Philippe Bachellier,Antonio Daniele Pinna,Gabriela A. Berlakovich,William Bennet,Massimo Pinzani,Peter Schemmer,Krzysztof Zieniewicz,Carlos Jimenez Romero,Paolo De Simone,Bo-Göran Ericzon,Stefan Schneeberger,Stephen J. Wigmore,Joan Fabregat Prous,Michele Colledan,Robert J. Porte,Sezai Yilmaz,Daniel Azoulay,Jacques Pirenne,Pål-Dag Line,Pavel Trunecka,Francis Navarro,Andres Valdivieso Lopez,Luciano De Carlis,Sebastian Rufian Pena,Eberhard Kochs,Christophe Duvoux +43 more
TL;DR: An overview of trends and results of liver transplantation in Europe from 1968 to 2016 is provided, as well as information on evolution of techniques, and outcomes in LT in Europe over more than five decades is provided.
Journal ArticleDOI
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma
Andreas A. Schnitzbauer,Carl Zuelke,Christian Graeb,Justine Rochon,Itxarone Bilbao,Patrizia Burra,Koert P. de Jong,Christophe Duvoux,Norman M. Kneteman,René Adam,Wolf O. Bechstein,Thomas Becker,Susanne Beckebaum,Olivier Chazouillères,Umberto Cillo,Michele Colledan,Fred Fändrich,Jean Gugenheim,Johann Hauss,Michael Heise,Ernest Hidalgo,Neville V. Jamieson,Alfred Königsrainer,P. Lamby,Jan Lerut,Heikki Mäkisalo,Raimund Margreiter,Vincenzo Mazzaferro,Ingrid Mutzbauer,Gerd Otto,Georges-Philippe Pageaux,Antonio Daniele Pinna,Jacques Pirenne,Magnus Rizell,Giorgio Rossi,Lionel Rostaing,André Roy,Victor Sanchez Turrion,Jan Schmidt,Roberto Troisi,Bart van Hoek,Umberto Valente,Philippe Wolf,Heiner Wolters,Darius F. Mirza,T. Scholz,Rudolf Steininger,Gunnar Söderdahl,Simone I. Strasser,Karl-Walter Jauch,Peter Neuhaus,Hans J. Schlitt,Edward K Geissler +52 more
TL;DR: If the hypothesis is correct that mTOR inhibition can reduce HCC tumour growth while simultaneously providing immunosuppression to protect the liver allograft from rejection, patients should experience less post-transplant problems with HCC recurrence, and therefore could expect a longer and better quality of life.
Journal ArticleDOI
Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC
Andrea Notarpaolo,Richard Layese,Paolo Magistri,Maria Gambato,Michele Colledan,G. Magini,L. Miglioresi,Alessandro Vitale,Giovanni Vennarecci,Cecilia D Ambrosio,Patrizia Burra,Fabrizio Di Benedetto,Stefano Fagiuoli,Marco Colasanti,Giuseppe Maria Ettorre,Arnoldo Andreoli,Umberto Cillo,Alexis Laurent,Sandrine Katsahian,Etienne Audureau,Françoise Roudot-Thoraval,Christophe Duvoux +21 more
TL;DR: The results confirm that in this specific population, as in the original French population of patients, the AFP model better selects patients with HCC eligible for transplantation, compared to Milan criteria, and can also be implemented in countries with an important burden of HCC occurring on post-hepatitic cirrhosis.